Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Glioma × Naltrexone × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Obesity 3 Breast Neoplasms 3 Overweight 2 Substance Withdrawal Syndrome 1 Skin Neoplasms 1 Prostatic Neoplasms 1 Metabolic Syndrome 1 Melanoma 1 Inflammation 1 Glioma 1 Glioblastoma 1 Dyslipidemias 1 Chronic Pain 1 Carcinoma, Lobular 1 Carcinoma, Intraductal, Noninfiltrating 1 Breast Carcinoma In Situ 1

Interventions

Temozolomide 134 Bevacizumab 62 Radiotherapy 58 Magnetic Resonance Spectroscopy 57 Irinotecan 25 Surgical Procedures, Operative 22 Carboplatin 22 Radiation 19 Specimen Handling 17 Carmustine 17 Aminolevulinic Acid 17 Blood Specimen Collection 16 Nivolumab 15 Biopsy 15 Lomustine 14 pembrolizumab 13 Radiotherapy, Intensity-Modulated 12 trametinib 11 Radiosurgery 11 X-Rays 10 Cyclophosphamide 10 fluorodopa F 18 9 Topotecan 9 IL13-PE38 9 Everolimus 9 ribociclib 8 dabrafenib 8 Surveys and Questionnaires 8 Imatinib Mesylate 8 Filgrastim 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01303835 2015-07-17

Low Dose Naltrexone for Glioma Patients

Duke University

Phase 2 Completed

110 enrolled 9 charts

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡